Panag Pharma Completes Phase 3 Trial With Awaye™

Recently acquired by Tetra Bio-Pharma, Panag Pharma’s terpene-derived topical product is aimed at pain caused by osteoarthritis of the knee #TBP #TBPMF OTTAWA, June 11, 2019 (GLOBE NEWSWIRE) — Panag Pharma Inc., a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX-V: TBP) (OTCQB: TBPMF), today announced completion of Panag 001, its Phase 3 clinical